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Available online 6 September 2014The metabolic syndrome is deﬁned by a constellation of car-
diometabolic risk factors that include abdominal obesity, elevated
blood sugar, high blood pressure, low high-density lipoprotein
(HDL) cholesterol and elevated triglycerides. The metabolic syn-
drome is diagnosed when 3 of these 5 risk factors are present [1].
Underlying these metabolic risk factors is adipose tissue dysfunc-
tion and insulin resistance which leads to an increase in circulating
free fatty acids (FFA). Increased FFA delivery to the liver increases
hepatic secretion and triglyceride enrichment of very-low density
lipoprotein (VLDL) cholesterol. Incomplete lipolysis of VLDL parti-
cles leads to an accumulation of triglyceride-rich remnant lipo-
proteins and triglyceride enrichment of HDL cholesterol via
cholesteryl ester transfer protein (CETP) results in smaller HDL
particles and low levels of HDL cholesterol [2]. Although low-
density lipoprotein (LDL) cholesterol is not speciﬁcally part of the
metabolic syndrome, individuals with the metabolic syndrome
have a high concentration of small dense LDL cholesterol particles.
The atherogenic dyslipidemia associated with the metabolic syn-
drome is an important risk factor for atherosclerosis and cardio-
vascular (CV) disease. The presence of the metabolic syndrome is
associated with a 2-fold increased risk of CV disease and a 5-fold
increased risk of diabetes [3].
The prevalence of the metabolic syndrome worldwide is on the
rise. This is due to an increase in the rates of obesity in both adults
and children, especially in developing countries [4]. Most deaths
related to the metabolic syndrome are attributable to CV disease
and this is mediated in large part by the hypertension andDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.08.023.
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management of the metabolic syndrome is lifestyle intervention;
however when lifestyle changes alone are unsuccessful, pharma-
cologic therapy to target the high blood pressure and dyslipidemia
associated with the metabolic syndrome is recommended. Statins
are the drug of choice to target the dyslipidemia associatedwith the
metabolic syndrome and are effective in lowering not only LDL
cholesterol, but also lower triglyceride-rich remnant lipoproteins
and have favorable effects on the size and concentration of LDL
cholesterol particles [5]. Post-hoc analyses from several clinical
outcome studies have shown that statin therapy reduces major CV
event in patients with the metabolic syndrome [6,7] and subgroup
analyses from other clinical trials suggest that ﬁbrates, niacin and
omega-3 fatty acids may further reduce CV risk in statin treated
patients with high triglycerides and low HDL cholesterol [8e10].
Although the new ACC/AHA cholesterol lowering guidelines [11] do
not speciﬁcally address the metabolic syndrome nor set cholesterol
goals for treatment, most individuals who have the metabolic
syndrome will have a high CV risk score or other indications that
would warrant statin therapy. The National Lipid Association [12]
and several international societies [13,14] also recommend lipid-
lowering therapy for individuals with the metabolic syndrome
and in contrast to the ACC/AHA cholesterol guidelines have set both
LDL and non-HDL cholesterol goals for these patients. The question
then is how successful have we been as clinicians in treating the
dyslipidemia associated with the metabolic syndrome?
In this issue of Atherosclerois, Wang and colleagues [15] help
answer this question. They evaluated the use of lipid-lowering
drugs and lipid goal attainment in patients with the metabolic
syndrome from the large observational Dyslipidemia International
Study of China (DYSIS-China). In this large study of 25, 697 patients
of varying CV risk, over one-third had the metabolic syndrome.
Among these patients 37% had coronary heart disease and 57% had
type 2 diabetes. Patients with the metabolic syndrome were less
likely to achieve their LDL and non-HDL cholesterol goals compared
to patients without the metabolic syndrome. LDL cholesterol goal
attainment was achieved in 47% of patients with the metabolic
syndrome compared to 69% in those without the metabolic syn-
drome (p < 0.001). Non-HDL cholesterol goals were achieved in 51%
of patients with the metabolic syndrome compared to 72% in those
without themetabolic syndrome (p < 0.001). The higher the CV riskr the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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very high-risk individuals only 26% achieved their LDL cholesterol
goal and 42% their non-HDL cholesterol goal. CV disease, diabetes,
and systolic hypertension were some of the factors associated with
failure to achieve optimal lipid goals. Almost all patients were on
statin therapy, though the use of non-statin or combination lipid-
lowering therapy was low as was the use of high potency statins.
Among patients with the metabolic syndrome only 35% were
treated with atorvastatin and 8% with rosuvastatin. The authors
concluded that clinicians should consider more intense lipid-
lowering therapy with combination lipid-lowering drugs in pa-
tients with themetabolic syndrome to better target their lipid goals
and further reduce CV risk. These ﬁndings are not a surprise and are
consistent with other studies that have shown that most high-risk
patients do not achieve their optimal LDL and non-HDL cholesterol
goals in clinical practice [16,17].
The strengths of this study are the large patient number and that
the analysis was performed not just by the Chinese guidelines, but
also by the American NCEP ATP III guidelines. The ﬁndings were
similar irrespective of whether the American or Chinese guidelines
were used. In themultinational L-TAP 2 survey only 30% of coronary
heart disease patients achieved an optimal LDL cholesterol goal of
<70 mg/dL [17]. The survey was conducted from 2006 to 2007 in
over 10,000 patients from 9 countries and spanning 3 continents.
Although it is somewhat difﬁcult to compare L-TAP 2 with the
current study by Wang and colleagues it appears that optimal lipid
goal attainment in high-risk patients has not improved much since
that survey was conducted. In the study by Wang and colleagues,
what lifestyle interventions if any were performed and the doses of
statins used were not reported? These are limitations of the study,
however previous studies have shown that most high-risk patients
are not prescribed a high intensity statin regimen. In a study of
9950 coronary artery disease patients in the United States, only 17%
were on a high intensity statin regimen and 27% on combination
lipid-lowering therapy [18]. Wang and colleagues found that the
majority of metabolic syndrome patients fell into a very high or
high-risk category and one explanation for why patients with the
metabolic syndrome fail to achieve their optimal lipid goals is that
they are assigned more aggressive lipid goals because of their
higher risk.
So what are the clinical implications of the study by Wang and
colleagues and how do we interpret their results in light of the
current guidelines in cholesterol management? The study byWang
and colleagues highlights the fact that the metabolic syndrome and
achieving optimal lipid goals in these patients are global health
problems. We need a better understanding as to why patients with
the metabolic syndrome are not achieving their optimal lipid goals
and there are several possible reasons for this. Clinicians may un-
derestimate the increased CV risk associated with the metabolic
syndrome, patients may be intolerant to higher intensity statin
drugs, and the lack of positive clinical outcome studies evaluating
combination lipid-lowering therapy in high-risk patients may
dissuade clinicians from using multiple lipid-lowering drugs in
combination. Many patients with the metabolic syndrome will be
considered high-risk and their LDL and non-HDL cholesterol goals
may be difﬁcult to achieve with statin therapy alone. Patient and
physician awareness regarding the dyslipidemia and increased CV
risk associated with the metabolic syndrome is needed. In patients
with the metabolic syndrome, non-HDL cholesterol may be a better
predictor of CV risk than LDL cholesterol. Among individuals with a
discordantly high non-HDL compared to LDL cholesterol, CV risk
may be underestimated when only LDL cholesterol is considered
[19]. To this point the recent NLA cholesterol guidelines have placed
non-HDL ahead of LDL cholesterol as a therapeutic target [12]. In
addition clinical outcome studies of combination lipid-loweringtherapy in patients with the metabolic syndrome who are inade-
quately treated with statin monotherapy are needed. However,
even with a high intensity statin and combination lipid-lowering
therapy many of these patients will not achieve their optimal
lipid goals [20]. To improve lipid goal attainment and reduce CV risk
worldwide we need to develop and implement better ways of
addressing lifestyle changes to battle the increasing global rates of
obesity and diabetes. Lifestyle changes can result in signiﬁcant
improvement in most components of the metabolic syndrome [21].
People in various parts of the world are more similar than
different and we all share the propensity to develop atherosclerosis
and CV disease, especially when lifestyle risk factors are not
controlled. Pharmacologic therapy to treat the dyslipidemia asso-
ciated with the metabolic syndrome will play an important role in
reducing CV risk in these patients. However if we do not focus on
real changes in lifestyle, as the world population grows larger so
will their waistline and risk of CV disease.Conﬂict of interest
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